Depolarization of mitochondrial membrane potential is the initial event in non-nucleoside reverse transcriptase inhibitor efavirenz induced cytotoxicity

被引:58
|
作者
Ganta, Krishna Kumar [1 ]
Mandal, Anirban [1 ]
Chaubey, Binay [1 ,2 ,3 ]
机构
[1] Univ Calcutta, Dept Bot, Ctr Adv Study, Funct Genom Lab, 35 Ballygunge Circular Rd, Kolkata 700019, India
[2] Univ Gdansk, Intercollegiate Fac Biotechnol, Dept Recombinant Vaccines, Kladki 24, PL-80822 Gdansk, Poland
[3] Med Univ Gdansk, Kladki 24, PL-80822 Gdansk, Poland
关键词
Apoptosis; Cytotoxicity; Efavirenz; Mitochondrial membrane potential; HIV-INFECTED PATIENTS; CYTOCHROME-C RELEASE; CHRONIC HEPATITIS-C; ANTIRETROVIRAL THERAPIES; PLASMA-CONCENTRATIONS; TARGETING DRUGS; CELL-DEATH; APOPTOSIS; EXPRESSION; TOXICITY;
D O I
10.1007/s10565-016-9362-9
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Efavirenz is a non-nucleoside reverse transcriptase inhibitor (NNRTI) and an active constituent of the highly active antiretroviral therapy regime. It has significantly contributed in control and management of human immunodeficiency virus propagation. However, EFV administration has also led to severe adverse effects, several reports highlighted the role of EFV in mitochondrial dysfunction and toxicity but the molecular mechanism has been poorly understood. In present study, human hepatoma cells Huh 7.5 were treated with clinically relevant concentrations of EFV and parameters like cytotoxicity, mitochondrial transmembrane potential, mitochondrial morphology, cytochrome c release, mitochondria-mediated apoptosis, mtDNA and mtRNA levels and EFV distribution into mitochondrial compartment were evaluated to understand sequence of events leading to cell death in EFV-treated cells. EFV at its clinically relevant concentration was significantly toxic after 48 and 72 h of treatments. EFV-mediated toxicity is initiated with the permeabilization of mitochondrial outer membrane and change in mitochondrial membrane potential (Delta psi m) which triggers a series of events like cytochrome c release, alteration in mitochondrial morphology and mitochondria-mediated apoptosis. Total mitochondrial content is reduced after 48 h of EFV treatment at IC50 concentration which is also reflected in reduced mitochondrial DNA and RNA levels. After detecting EFV in mitochondrial compartment after 12 h of incubation with EFV, we hypothesize that EFV being a lipophilic molecule is internalized into the mitochondrial compartment causing depolarization of Delta psi m which subsequently leads to a cascade of events causing cell death.
引用
收藏
页码:69 / 82
页数:14
相关论文
共 50 条
  • [1] Depolarization of mitochondrial membrane potential is the initial event in non-nucleoside reverse transcriptase inhibitor efavirenz induced cytotoxicity
    Krishna Kumar Ganta
    Anirban Mandal
    Binay Chaubey
    Cell Biology and Toxicology, 2017, 33 : 69 - 82
  • [2] Synthesis and biological activities of potential metabolites of the non-nucleoside reverse transcriptase inhibitor efavirenz
    Markwalder, JA
    Mutlib, DDCA
    Cordova, BC
    Klabe, RM
    Seitz, SP
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2001, 11 (05) : 619 - 622
  • [3] Non-nucleoside reverse transcriptase inhibitor efavirenz activates PXR to induce hypercholesterolemia and hepatic steatosis
    Gwag, Taesik
    Meng, Zhaojie
    Su, Yipeng
    Helsley, Robert N.
    Park, Se-Hyung
    Wang, Shuxia
    Greenberg, Richard N.
    Zhou, Changcheng
    JOURNAL OF HEPATOLOGY, 2019, 70 (05) : 930 - 940
  • [4] Method to measure human plasma concentrations of the non-nucleoside reverse transcriptase inhibitor efavirenz (EFV).
    Villani, P
    Maserati, R
    Seminari, E
    Gambarana, E
    Pregnolato, M
    Regazzi, MB
    AIDS, 1998, 12 : S30 - S30
  • [5] Rilpivirine: a new non-nucleoside reverse transcriptase inhibitor
    Sharma, Mamta
    Saravolatz, Louis D.
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2013, 68 (02) : 250 - 256
  • [6] Rilpivirine: a novel non-nucleoside reverse transcriptase inhibitor
    Garvey, Lucy
    Winston, Alan
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2009, 18 (07) : 1035 - 1041
  • [7] Interactions between non-nucleoside reverse transcriptase inhibitor and nucleoside reverse transcriptase inhibitor mutations: phenotypes and mechanisms
    Shulman, Nancy S.
    CURRENT OPINION IN HIV AND AIDS, 2007, 2 (02) : 88 - 93
  • [8] The pharmacokinetics of methadone in HIV-positive patients receiving the non-nucleoside reverse transcriptase inhibitor efavirenz
    Clarke, SM
    Mulcahy, FM
    Tjia, J
    Reynolds, HE
    Gibbons, SE
    Barry, MG
    Back, DJ
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2001, 51 (03) : 213 - 217
  • [9] Determination of the non-nucleoside reverse transcriptase inhibitor efavirenz in human plasma by gas chromatography mass spectrometry
    Kankaanpaa, Aino
    Turtiainen, Saija
    Meririnne, Esa
    Arinierm, Kari
    Ristola, Matti
    Kuoppasalmi, Kimmo
    THERAPEUTIC DRUG MONITORING, 2007, 29 (04) : 513 - 514
  • [10] Simultaneous quantification of a non-nucleoside reverse transcriptase inhibitor efavirenz, a nucleoside reverse transcriptase inhibitor emtricitabine and a nucleotide reverse transcriptase inhibitor tenofovir in plasma by liquid chromatography positive ion electrospray tandem mass spectrometry
    Nirogi, Ramakrishna
    Bhyrapuneni, Gopinadh
    Kandikere, Vishwottam
    Mudigonda, Koteshwara
    Komarneni, Prashanth
    Aleti, Raghupathi
    Mukkanti, K.
    BIOMEDICAL CHROMATOGRAPHY, 2009, 23 (04) : 371 - 381